TGFB Inhibitor Pipeline Gains Momentum with Emerging Immunotherapies and Targeted Oncology Approaches | DelveInsight

DelveInsight's "Transforming Growth Factor Beta (TGFB) Inhibitor Pipeline Insight, 2026" report provides comprehensive global coverage of available, marketed, and pipeline TGFB inhibitor therapies in various stages of clinical development. Several pharmaceutical and biotechnology companies are actively working to advance the TGFB inhibitor pipeline landscape and expand future therapeutic opportunities across oncology and fibrotic diseases.

Key takeaways from the TGFB Inhibitor Pipeline Report
• DelveInsight's TGFB inhibitor pipeline report depicts a developing therapeutic landscape with multiple active companies evaluating innovative therapies targeting the TGF-β signaling pathway.
• Key TGFB inhibitor companies such as EpicentRx, Sirnaomics, Scholar Rock, iOnctura, and SiSaf are actively developing novel therapies in this space.
• Promising TGFB inhibitor pipeline therapies in different stages of development include AdAPT-001, STP 707, SRK-181, IOA-359, SIS 201 CD, and others.
• The pipeline includes a diverse range of therapeutic modalities such as immunotherapies, monoclonal antibodies, small interfering RNA (siRNA), and targeted small molecules.
• TGFB inhibitors are being investigated across multiple indications including solid tumors, sarcoma, non-small cell lung cancer (NSCLC), fibrosis, and other oncology-focused conditions.

Request a sample and discover the recent advances in TGFB inhibitor therapies https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What are TGFB Inhibitors?
Transforming Growth Factor Beta (TGFB) inhibitors are compounds designed to block the activity of TGF-β, a multifunctional cytokine involved in cell growth, differentiation, immune regulation, fibrosis, tumor progression, and metastasis.
TGF-β signaling plays a critical role in promoting epithelial-mesenchymal transition (EMT), tumor invasion, fibrosis, and immune suppression. TGFB inhibitors work by targeting different components of the signaling pathway through neutralizing antibodies, ligand traps, and receptor kinase inhibitors. These therapies aim to suppress downstream SMAD signaling and reduce pro-fibrotic, immunosuppressive, and tumor-promoting activities.
The therapeutic importance of TGFB inhibitors continues to grow due to their potential to improve anti-tumor immunity, reduce metastatic progression, enhance responses to checkpoint inhibitors, and manage fibrotic diseases. Their broad applicability makes them promising candidates for combination therapies across several therapeutic areas.

Emerging TGFB Inhibitor Drug Profiles
AdAPT-001: EpicentRx
AdAPT-001 is a novel investigational immunotherapy developed by EpicentRx utilizing a replicative type 5 adenovirus engineered with a TGF-β receptor-immunoglobulin Fc fusion trap. The therapy is designed to neutralize TGF-β isoforms 1 and 3 associated with fibrosis, angiogenesis, hypoxia, and immune suppression within the tumor microenvironment.
The therapy aims to improve tumor sensitivity to checkpoint blockade therapies while potentially reducing toxicity associated with traditional checkpoint inhibitors. AdAPT-001 is currently in Phase II clinical development for multiple tumor types including soft tissue sarcoma, colorectal cancer, breast cancer, and hepatocellular carcinoma.
STP 707: Sirnaomics
STP 707 is an investigational small interfering RNA (siRNA) therapy being developed by Sirnaomics for solid tumors. The therapy is administered intravenously and is currently in Phase I clinical development.
The candidate highlights the growing interest in RNA-based approaches targeting the TGFB pathway to suppress tumor progression and modulate the tumor microenvironment.

Learn more about the novel and emerging TGFB inhibitor pipeline therapies https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the TGFB Inhibitor Pipeline Landscape
• In March 2021, EpicentRx initiated a Phase IIa/IIb clinical trial evaluating AdAPT-001 in patients with refractory solid tumors.
• In December 2024, EpicentRx announced that the US Food and Drug Administration (FDA) granted Fast Track designation to AdAPT-001 in combination with nivolumab or atezolizumab for recurrent or refractory advanced or metastatic soft tissue sarcoma.
• Clinical trial findings demonstrated that AdAPT-001 combined with checkpoint inhibitors improved progression-free survival and showed encouraging activity in angiosarcoma patients.
• In July 2025, Keros Therapeutics announced that the first patient was dosed in the Phase III RENEW clinical trial evaluating elritercept in adults with transfusion-dependent anemia associated with myelodysplastic syndromes.
• In May 2025, KaliVir Immunotherapeutics announced successful completion of the first cohort in its STEALTH-001 Phase I/Ib clinical trial evaluating VET3-TGI in patients with advanced solid tumors.

Scope of the TGFB Inhibitor Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Monotherapy, Combination Therapy
• Therapeutic Assessment By Clinical Stages: Discovery, Preclinical, Phase I, Phase I/II, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Intratumoral, Ophthalmic, and Unspecified
• Therapeutics Assessment By Molecule Type: Immunotherapy, Monoclonal antibodies, Small interfering RNA, Small molecules
• Key TGFB Inhibitor Companies: EpicentRx, Sirnaomics, Scholar Rock, iOnctura, SiSaf, and others
• Key TGFB Inhibitor Pipeline Therapies: AdAPT-001, STP 707, SRK-181, IOA-359, SIS 201 CD, and others

Dive deep into rich insights for emerging TGFB inhibitor therapies, visit https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. TGFB Inhibitor Pipeline Report Introduction
2. Executive Summary
3. Transforming Growth Factor Beta (TGFB) Inhibitor Overview
4. TGFB Inhibitor Mechanism of Action
5. Therapeutic Applications of TGFB Inhibitors
6. Pipeline Therapeutics
7. Comparative Analysis
8. Late-stage Products (Phase III)
9. Mid-stage Products (Phase II)
10. Early-stage Products (Phase I/II)
11. Early-stage Products (Phase I)
12. Preclinical Stage Products
13. Therapeutic Assessment
14. Assessment by Product Type
15. Assessment by Route of Administration
16. Assessment by Indication
17. Assessment by Stage and Indication
18. Inactive Products
19. Collaborations Assessment- Licensing / Partnering / Funding
20. TGFB Inhibitor Unmet Needs
21. TGFB Inhibitor Market Drivers and Barriers
22. Appendix

For further information on the TGFB inhibitor pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.